(VRSK) Verisk Analytics - Ratings and Ratios
Analytics, Underwriting, Claims, Catastrophe, Fraud
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.83% |
| Yield on Cost 5y | 0.91% |
| Yield CAGR 5y | 9.63% |
| Payout Consistency | 100.0% |
| Payout Ratio | 25.9% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 19.2% |
| Value at Risk 5%th | 29.8% |
| Relative Tail Risk | -5.69% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.07 |
| Alpha | -30.00 |
| CAGR/Max DD | 0.25 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.406 |
| Beta | 0.285 |
| Beta Downside | 0.272 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.06% |
| Mean DD | 6.03% |
| Median DD | 3.56% |
Description: VRSK Verisk Analytics December 17, 2025
Verisk Analytics, Inc. (NASDAQ: VRSK) supplies data-analytics and technology services to insurers worldwide, covering underwriting, claims, fraud detection, catastrophe modelling, and specialty-business management. Its offerings span rule-based underwriting forms, loss-cost analytics, workflow automation, and international solutions for both property-casualty and life insurance markets.
Key metrics (FY 2023) show revenue of roughly $3.1 billion with an operating margin near 22 %, driven largely by subscription-based recurring revenue that now represents about 70 % of total sales. The company’s growth is anchored to macro-level drivers such as rising natural-catastrophe frequency, which fuels demand for its extreme-event modelling, and tightening regulatory environments that increase the need for compliance and anti-fraud tools. Additionally, the broader insurance-tech sector is seeing a shift toward AI-enhanced underwriting, positioning Verisk’s data assets as a competitive moat.
If you’re evaluating how Verisk’s platform stacks up against newer analytics players, a quick look at ValueRay’s product suite could provide useful context.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (921.4m TTM) > 0 and > 6% of Revenue (6% = 181.8m TTM) |
| FCFTA 0.18 (>2.0%) and ΔFCFTA -2.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.40% (prev -8.59%; Δ 22.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.22 (>3.0%) and CFO 1.35b > Net Income 921.4m (YES >=105%, WARN >=100%) |
| Net Debt (2.78b) to EBITDA (1.66b) ratio: 1.68 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.19 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (139.9m) change vs 12m ago -1.80% (target <= -2.0% for YES) |
| Gross Margin 69.62% (prev 68.24%; Δ 1.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.08% (prev 61.87%; Δ -5.80pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.09 (EBITDA TTM 1.66b / Interest Expense TTM 148.5m) >= 6 (WARN >= 3) |
Altman Z'' 7.54
| (A) 0.07 = (Total Current Assets 2.70b - Total Current Liabilities 2.26b) / Total Assets 6.24b |
| (B) 1.23 = Retained Earnings (Balance) 7.68b / Total Assets 6.24b |
| warn (B) unusual magnitude: 1.23 — check mapping/units |
| (C) 0.25 = EBIT TTM 1.35b / Avg Total Assets 5.40b |
| (D) 1.33 = Book Value of Equity 7.78b / Total Liabilities 5.86b |
| Total Rating: 7.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.21
| 1. Piotroski 5.50pt |
| 2. FCF Yield 3.38% |
| 3. FCF Margin 36.83% |
| 4. Debt/Equity 12.98 |
| 5. Debt/Ebitda 1.68 |
| 6. ROIC - WACC (= 19.75)% |
| 7. RoE 404.3% |
| 8. Rev. Trend 35.24% |
| 9. EPS Trend 75.09% |
What is the price of VRSK shares?
Over the past week, the price has changed by +0.95%, over one month by -0.46%, over three months by -13.40% and over the past year by -22.12%.
Is VRSK a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 10
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the VRSK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 251.3 | 15.5% |
| Analysts Target Price | 251.3 | 15.5% |
| ValueRay Target Price | 210.2 | -3.4% |
VRSK Fundamental Data Overview December 11, 2025
P/E Trailing = 33.2354
P/E Forward = 28.0899
P/S = 9.9629
P/B = 81.0115
P/EG = 2.6863
Beta = 0.814
Revenue TTM = 3.03b USD
EBIT TTM = 1.35b USD
EBITDA TTM = 1.66b USD
Long Term Debt = 3.21b USD (from longTermDebt, last quarter)
Short Term Debt = 1.52b USD (from shortTermDebt, last quarter)
Debt = 4.89b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 32.96b USD (30.18b + Debt 4.89b - CCE 2.11b)
Interest Coverage Ratio = 9.09 (Ebit TTM 1.35b / Interest Expense TTM 148.5m)
FCF Yield = 3.38% (FCF TTM 1.12b / Enterprise Value 32.96b)
FCF Margin = 36.83% (FCF TTM 1.12b / Revenue TTM 3.03b)
Net Margin = 30.41% (Net Income TTM 921.4m / Revenue TTM 3.03b)
Gross Margin = 69.62% ((Revenue TTM 3.03b - Cost of Revenue TTM 920.3m) / Revenue TTM)
Gross Margin QoQ = 70.13% (prev 70.30%)
Tobins Q-Ratio = 5.28 (Enterprise Value 32.96b / Total Assets 6.24b)
Interest Expense / Debt = 0.86% (Interest Expense 42.2m / Debt 4.89b)
Taxrate = 25.36% (76.6m / 302.1m)
NOPAT = 1.01b (EBIT 1.35b * (1 - 25.36%))
Current Ratio = 1.19 (Total Current Assets 2.70b / Total Current Liabilities 2.26b)
Debt / Equity = 12.98 (Debt 4.89b / totalStockholderEquity, last quarter 376.7m)
Debt / EBITDA = 1.68 (Net Debt 2.78b / EBITDA 1.66b)
Debt / FCF = 2.49 (Net Debt 2.78b / FCF TTM 1.12b)
Total Stockholder Equity = 227.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.76% (Net Income 921.4m / Total Assets 6.24b)
RoE = 404.3% (Net Income TTM 921.4m / Total Stockholder Equity 227.9m)
RoCE = 39.23% (EBIT 1.35b / Capital Employed (Equity 227.9m + L.T.Debt 3.21b))
RoIC = 25.92% (NOPAT 1.01b / Invested Capital 3.89b)
WACC = 6.17% (E(30.18b)/V(35.07b) * Re(7.07%) + D(4.89b)/V(35.07b) * Rd(0.86%) * (1-Tc(0.25)))
Discount Rate = 7.07% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.89%
[DCF Debug] Terminal Value 79.70% ; FCFE base≈1.03b ; Y1≈1.14b ; Y5≈1.49b
Fair Price DCF = 185.2 (DCF Value 25.81b / Shares Outstanding 139.4m; 5y FCF grow 12.29% → 3.0% )
EPS Correlation: 75.09 | EPS CAGR: 4.28% | SUE: 0.39 | # QB: 0
Revenue Correlation: 35.24 | Revenue CAGR: 0.08% | SUE: -1.49 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.82 | Chg30d=-0.031 | Revisions Net=-8 | Analysts=15
EPS next Year (2026-12-31): EPS=7.65 | Chg30d=-0.031 | Revisions Net=-7 | Growth EPS=+10.2% | Growth Revenue=+8.9%
Additional Sources for VRSK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle